These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30980209)

  • 1. Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review.
    Coory M; Thornton K
    Breast Cancer Res Treat; 2019 Jul; 176(1):17-25. PubMed ID: 30980209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
    Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
    Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):357-371. PubMed ID: 31175632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
    Giuliani J; Bonetti A
    Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Trastuzumab and its biosimilars].
    Sarosiek T; Morawski P
    Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
    Kirsch-Stefan N; Guillen E; Ekman N; Barry S; Knippel V; Killalea S; Weise M; Wolff-Holz E
    BioDrugs; 2023 Nov; 37(6):855-871. PubMed ID: 37831324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
    Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
    Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars.
    Barbier L; Declerck P; Simoens S; Neven P; Vulto AG; Huys I
    Br J Cancer; 2019 Jul; 121(3):199-210. PubMed ID: 31257362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
    Kim WS; Coiffier B; Kwon HC; Kim S
    Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Clinical Review of Biosimilars Approved in Oncology.
    Ngo D; Chen J
    Ann Pharmacother; 2021 Mar; 55(3):362-377. PubMed ID: 32715722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
    Paplomata E; Nahta R
    Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis.
    Luo X; Du X; Li Z; Liu J; Lv X; Li H; Guo Q; Wang C; Xue X; Le K; Jiang X; Huang L; Yang Y
    JAMA Netw Open; 2023 Oct; 6(10):e2337348. PubMed ID: 37824143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis
.
    Mengato D; Chiumente M; Messori A
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):160-162. PubMed ID: 30574866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.
    Jacobs I; Ewesuedo R; Lula S; Zacharchuk C
    BioDrugs; 2017 Feb; 31(1):1-36. PubMed ID: 28078656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evidence supporting the marketing authorization of biosimilars in Europe.
    Allocati E; Bertele' V; Gerardi C; Garattini S; Banzi R
    Eur J Clin Pharmacol; 2020 Apr; 76(4):557-566. PubMed ID: 31897530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
    Stebbing J; Mainwaring PN; Curigliano G; Pegram M; Latymer M; Bair AH; Rugo HS
    J Clin Oncol; 2020 Apr; 38(10):1070-1080. PubMed ID: 32058846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Milestones over the development of SB3, a trastuzumab biosimilar.
    Pivot X; Bondarenko I; Petit T; Curtit E
    Future Oncol; 2018 Nov; 14(27):2795-2803. PubMed ID: 29927335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
    Hara F; Tajima K; Tanabe K
    Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.